Clincosm LogoSign in Get a demo

pcnsl

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Recruiting
  • PCNSL
  • Milan, Italy
    Ospedale San Raffaele
Mar 13, 2023

Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

Recruiting
  • Primary Central Nervous System Lymphoma
  • +2 more
  • Guandong, Guangdong, China
  • +2 more
Apr 6, 2022

Factors in Patients With Primary Central Nervous System Lymphoma

Recruiting
  • PCNSL
  • Survival Analysis
  • prognostic marker
  • Zhengzhou, Henan, China
    Zhengzhou university
Dec 12, 2021

Refractory and Relapsed Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guangzhou (Orelabrutinib, Thiotepa)

Not yet recruiting
  • Refractory and Relapsed Primary CNS Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Aug 19, 2021

PCNSL, Secondary CNS Lymphoma Trial in Beijing, Guangzhou, Shanghai (ICP-022)

Recruiting
  • PCNSL
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
  • +4 more
Jul 28, 2021

PCNSL Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Recruiting
  • PCNSL
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 16, 2020

PCNSL Trial in Hwasun-gun (R-B(O)AD)

Unknown status
  • PCNSL
  • Hwasun-gun, Jeollanam-do, Korea, Republic of
    Chonnam National University Hwasun Hospital
Jan 2, 2018